CDK12 is often mutated in ovarian and prostate cancer and CDK12 deficiency may thus prove useful as a biomarker of PARP inhibitor response (The Cancer Genome Atlas Research Network 2011; Bajrami et al. 2014; Wu et al. 2018). Here, CDK12 is linked to prostate cancer.